NCT00636142View on ClinicalTrials.gov

Effects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human Obesity

PHASE4CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

September 30, 2007

Conditions
ObesityInsulin ResistanceMetabolic Syndrome
Interventions
BIOLOGICAL

Infliximab

5 mg/kg body weight, maximal dose 500 mg; intravenous administration

Trial Locations (1)

8036

Department of Internal Medicine, Medical University of Graz, Graz

All Listed Sponsors
lead

Medical University of Graz

OTHER

NCT00636142 - Effects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human Obesity | Biotech Hunter | Biotech Hunter